Domperidone for lactation: What health care providers really should know

In a recent commentary, Sewell et al lament the limited quality evidence for the effectiveness of domperidone for lactation enhancement in contrast to the apparent considerable information on domperidone's cardiac risk among lactating women.1 Such considerable information is either extrapolated from observational studies among nonlactating adults or restricted to a small number of adverse event reports submitted to the U.S. Food and Drug Administration, with the authors later highlighting the lack of reliable information from previous pharmacoepidemiologic studies to adequately inform the risk of harm in breastfeeding women.